Steven Cohen Myovant Sciences Ltd. Transaction History

Point72 Asset Management, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$18.94 - $26.99 $2.93 Million - $4.18 Million	-154,800 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$17.07 - $24.56 $1.99 Million - $2.86 Million	116,400 Added 303.13%	154,800 $3.53 Million
Q1 2021 May 17, 2021	BUY	$20.46 - $25.18 $785,664 - $966,912	38,400 New	38,400 $790,000
Q4 2019 Feb 14, 2020	SELL	$4.2 - $19.21 $861,840 - $3.94 Million	-205,200 Closed	0 $0
Q3 2019 Nov 15, 2019	SELL	$5.19 - $9.46 $3.37 Million - $6.14 Million	-649,286 Reduced 75.99%	205,200 $1.07 Million
Q2 2019 Aug 14, 2019	BUY	$8.69 - $25.0 $7.43 Million - $21.4 Million	854,486 New	854,486 $7.73 Million
Q4 2017 Feb 14, 2018	SELL	$11.37 - $16.4 $922,106 - $1.33 Million	-81,100 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$9.93 - $15.47 $805,323 - $1.25 Million	81,100	81,100 $1.26 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.